Clinical Trial Update: Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients

View source ↗

Summary

A completed clinical trial analysis evaluating the incidence of tumor antigen expression in Asiatic patients with stage I–III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC) | Status: COMPLETED